Report Overview

Vietnam Stomach Cancer Treatment Market - Industry Trends & Forecast Report, 2029

The Vietnam stomach cancer treatment market size is projected to grow at a CAGR of 11.24% during the forecast period of 2023–2029. Major growth factors for the Vietnam stomach cancer treatment market include changes in lifestyle, such as smoking and drinking, an increase in obesity, and a rise in gastroesophageal reflux syndrome. According to Epidemiological statistics from Vietnam, stomach and colon cancer continue to rank third and ninth, respectively, in terms of malignancy-related deaths in both sexes in the country. With increasing healthcare accessibility, the Vietnam Stomach cancer treatment market is projected to gain significant traction during the forecast period.

Vietnam Stomach Cancer Treatment Market – Overview

The abnormal proliferation of malignant cells within the stomach lining is a symptom of stomach cancer. Until it spreads to other regions of the body, this form of cancer is typically difficult to identify in its early stages. Chemotherapy, radiation, and occasionally surgery can be used to treat symptoms and enhance the quality of life in stomach cancer situations when the disease cannot be fully cured. As long as all of the malignant tissue can be removed, surgery can treat stomach cancer if it is treatable.

Vietnam Stomach Cancer Treatment Market

Growth Drivers

Increasing Prevalence of Stomach Cancer

In terms of stomach cancer incidence rates worldwide, Vietnam is one of the top 10 nations. In Vietnam, stomach cancer is the third most common type of cancer to be discovered; more than 17,500 new cases were discovered there in 2018. Due to the high incidence of stomach cancer, industry participants are making large investments in R&D projects to advance the disease's detection and care. Ho Chi Minh City’s Binh Dan Hospital, for instance, conducted the first stomach cancer surgery with robot arms for a male patient back in 2017. Such innovations are projected to boost the growth of the overall Vietnam stomach cancer treatment market during the forecast period.

Restraints

Lack of Skilled Professionals and High Cost of Treatment

The Vietnam stomach cancer treatment market's expansion may be restrained by a lack of skilled specialists who are unaware of the treatment options for stomach cancer. Additionally, the high cost of treatment procedures and the absence of reimbursement regulations undoubtedly restrain market expansion.

Impact of COVID-19 on the Vietnam Stomach Cancer Treatment Market

The COVID-19 pandemic hindered the growth of the Vietnam stomach cancer treatment market. The increasing burden of the covid19 patients led to a significant decline in non-COVID-19 patients' visits to healthcare facilities which resulted in delays in diagnosis and treatment. Due to greater hospital transmission rates, their frequent hospital visits would increase their chance of contracting COVID-19. As a result, chemotherapy patients faced a difficult choice: continuing treatment while raising their risk of infection or staying at home to put off starting their cancer therapies. Additionally, the pandemic had a big influence on stomach cancer clinical trials. The pandemic halted or delayed several research studies, which hampered the advancement of novel medications and treatments for the illness.

Vietnam Stomach Cancer Treatment Market

Segmental Coverage

Vietnam Stomach Cancer Treatment Market – By Treatment Type

Based on treatment type, the Vietnam stomach cancer treatment market is divided into immunotherapy, targeted therapy, chemotherapy, radiation therapy, and surgery segments. The chemotherapy segment accounts for the highest share of the Vietnam stomach cancer treatment market. Perioperative chemotherapy is the term used when chemotherapy is administered both before and after surgery. By reducing the tumor, this therapy increases the success of the surgery. This lessens the likelihood of cancer returning, which also contributes to its market growth.

Vietnam Stomach Cancer Treatment Market – By Disease Indication

Based on disease indication, the Vietnam stomach cancer treatment market is segmented into gastric cancer/gastroesophageal junction cancer and gastrointestinal stromal tumors. Gastric cancer/gastroesophageal junction cancer holds the largest market share. The growth of this disease indication type is mainly attributed to the increasing burden of gastric cancer/gastroesophageal junction cancer along with a large number of approved products for this indication.

Vietnam Stomach Cancer Treatment Market – By Route of Administration

Based on the route of administration, the Vietnam stomach cancer treatment market is segmented into oral and injectable. The injectable segment accounts for a higher share in the Vietnam stomach cancer treatment market, as most chemotherapy, targeted, and immunotherapy medications are only accessible in injectable form. During the forecast period, the oral segment is expected to grow at the fastest rate. Many businesses are creating oral chemotherapy drugs as a therapeutic option to replace laborious IV delivery.

Vietnam Stomach Cancer Treatment Market – By Drug Class

Based on drug class, the Vietnam stomach cancer treatment market is segmented into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and others. Chemotherapy is the most prominent type of treatment for stomach cancer and is considered the first line of treatment for such a disease. Palliative chemotherapy for stomach cancer has been shown to prolong life and enhance the quality of life, according to research. Following chemotherapy, PD-1/PD-L1 inhibitors are anticipated to gain lucrative growth during the forecast period.

Vietnam Stomach Cancer Treatment Market – By Distribution Channel

Based on distribution channel, the Vietnam stomach cancer treatment market is segmented into hospital pharmacies, specialty & retail pharmacies, and others. The specialty & retail pharmacies segment accounts for the highest share of the Vietnam stomach cancer treatment market. The majority of medications used to treat stomach cancer are provided by specialist pharmacies since they must be maintained and supplied under precise circumstances. Due to the high patient treatment of stomach cancer patients, the hospital segment also accounts for a sizable market share.

Competitive Landscape

Major players operating in the Vietnam stomach cancer treatment market include Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis, and Otsuka Holdings Co. Ltd. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In April 2022 – Artemis DNA, Inc., a US-based company, announced an international expansion with the opening in Ho Chi Minh City, Vietnam, offering its genetic testing technology and portfolio for the early detection of cancer, including stomach and colon cancer.

Scope of the Report

By Treatment Type

• Immunotherapy

• Targeted Therapy

• Chemotherapy

• Radiation Therapy and Surgery

By Disease Indication

• Gastric Cancer/Gastroesophageal Junction Cancer

• Gastrointestinal Stromal Tumors

By Route of Administration

• Oral

• Injectable

By Drug Class

• PD-1/PD-L1 Inhibitors

• HER2 Antagonists

• VEGFR2 Antagonists

• Others

By Distribution Channel

• Hospital Pharmacies

• Specialty & Retail Pharmacies

• Others

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. Vietnam Stomach Cancer Treatment Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Robust product pipeline
         2. Increasing prevalence of the disease
      2. Restraints
         1. Lack of reimbursement for currently approved targeted therapies
      3. Opportunities
         1. Presence of potential pipeline candidates
         2. Rising ageing population
      4. Challenges
         1. COVID-19 Impact
   3. Technology Landscape/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. Vietnam Stomach Cancer Treatment Market Overview
   1. Market Size & Forecast by Value, 2019–2029
      1. By Value (USD Million)
   2. Market Share & Forecast
      1. By Treatment Type
         1. Immunotherapy
         2. Targeted Therapy
         3. Chemotherapy
         4. Radiation Therapy and Surgery
      2. By Disease Indication
         1. Gastric Cancer/Gastroesophageal Junction Cancer
         2. Gastrointestinal Stromal Tumors
      3. By Route of Administration
         1. Oral
         2. Injectable
      4. By Drug Class
         1. PD-1/PD-L1 Inhibitors
         2. HER2 Antagonists
         3. VEGFR2 Antagonists
         4. Others
      5. By Distribution Channel
         1. Hospital Pharmacies
         2. Specialty & Retail Pharmacies
         3. Others
5. Competitive Landscape
   1. List of Key Players and Their Offerings
   2. Market Share Analysis, 2022
   3. Competitive Benchmarking, By Operating Parameters
   4. Key Strategic Development (Merger, Acquisition, Partnership.)
6. Impact of COVID-19 on Vietnam Stomach Cancer Treatment Market Industry
7. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
   1. Novartis AG
   2. Pfizer, Inc.
   3. Mylan N.V.
   4. F. Hoffmann La Roche Ltd.
   5. Eli Lilly And Company
   6. Merck & Co., Inc.
   7. Teva Pharmaceutical Industries Ltd.
   8. Samsung Bioepis
   9. Otsuka Holdings Co. Ltd.
   10. Other Prominent Players
8. Research Methodology
   1. Qualitative Research
      1. Primary & Secondary Research
   2. Quantitative Research
   3. Market Breakdown & Data Triangulation
      1. Secondary Research
      2. Primary Research
   4. Breakdown of Primary Research Respondents, By Region
   5. Assumption & Limitation
9. Key Strategic Recommendations

List of Figures

Figure 1       Vietnam Stomach Cancer Treatment Market Segmentation

Figure 2       Vietnam Stomach Cancer Treatment Market Value Chain Analysis

Figure 3       Porters Analysis

Figure 4       Vietnam Stomach Cancer Treatment Market Size, By Value (USD Million), 2019–2029

Figure 5       Vietnam Stomach Cancer Treatment Market Share, By Treatment Type, By Value, 2019–2029

Figure 6       Vietnam Stomach Cancer Treatment Market Share, By Disease Indication, By Value, 2019–2029

Figure 7       Vietnam Stomach Cancer Treatment Market Share, By Route of Administration, By Value, 2019–2029

Figure 8       Vietnam Stomach Cancer Treatment Market Share, By Drug Class, By Value, 2019–2029

Figure 9       Vietnam Stomach Cancer Treatment Market Share, By Distribution Channel, By Value, 2019–2029

Figure 10     Vietnam Stomach Cancer Treatment Company Market Share Analysis, 2022

List of Table

Table 1        Vietnam Stomach Cancer Treatment Market Size, By Treatment Type, By Value, 2019–2029

Table 2        Vietnam Stomach Cancer Treatment Market Size, By Disease Indication, By Value, 2019–2029

Table 3        Vietnam Stomach Cancer Treatment Market Size, By Route of Administration, By Value, 2019-2030

Table 4        Vietnam Stomach Cancer Treatment Market Size, By Drug Class, By Value, 2019–2029

Table 5        Vietnam Stomach Cancer Treatment Market Size, By Distribution Channel, By Value, 2019–2029

Table 6        Novartis AG Company Overview

Table 7        Novartis AG Financial Overview

Table 8        Pfizer, Inc. Company Overview

Table 9        Pfizer, Inc. Financial Overview

Table 10      Mylan N.V. Company Overview

Table 11      Mylan N.V. Financial Overview

Table 12      F. Hoffmann La Roche Ltd. Company Overview

Table 13      F. Hoffmann La Roche Ltd. Financial Overview

Table 14      Eli Lilly And Company: Company Overview

Table 15      Eli Lilly And Company Financial Overview

Table 16      Merck & Co., Inc. Company Overview

Table 17      Merck & Co., Inc. Financial Overview                                       

Table 18      Teva Pharmaceutical Industries Ltd. Company Overview

Table 19      Teva Pharmaceutical Industries Ltd. Financial Overview

Table 20      Samsung Bioepis Company Overview

Table 21      Samsung Bioepis Financial Overview

Table 22      Otsuka Holdings Co. Ltd Company Overview

Table 23      Otsuka Holdings Co. Ltd Financial Overview